A Phase 3 Peptide Stroke Trial Failed. The Severe-Stroke Signal Is Hard to Ignore

A phase 3 stroke trial has produced the kind of result that is both disappointing and genuinely interesting. The experimental combination, epidermal growth factor (EGF) plus growth hormone-releasing peptide-6 (GHRP-6), did not improve the main outcomes across the full study population. On the trial's primary question, it failed.

But buried inside the data was a much smaller group of patients with severe strokes. In that group, disability scores and mortality moved sharply in the right direction. The finding is not strong enough to change medical practice, and it may not survive a larger, properly targeted trial. Still, it gives researchers a specific question worth testing rather than another vague reason to “study the drug more.”

The COURAGE-2 results were published online July 16, 2026, in the Journal of Clinical Neuroscience. They also offer a useful lesson for anyone following peptide medicine: a plausible mechanism and encouraging early data can get a treatment to phase 3, but only a well-designed confirmatory trial can tell us whether the signal is real.

What COURAGE-2 tested

COURAGE-2 was a multicenter, randomized, open-label phase 3 trial involving 188 adults with acute ischemic stroke. Patients entered the study within 12 hours of symptom onset and had National Institutes of Health Stroke Scale (NIHSS) scores between 5 and 20. The average age was 63.5 years, 110 participants were men, and the average time from stroke onset to treatment was 7.3 hours.

Researchers assigned 95 patients to standard care plus intravenous EGF and GHRP-6. The remaining 93 received standard care alone. The treatment group received 75 micrograms of EGF and 5 milligrams of GHRP-6 twice daily for seven days.

The main clinical yardstick was the modified Rankin Scale, or mRS, measured at three and six months. The scale runs from no symptoms through severe disability to death. Researchers also tracked survival, the Barthel Index for daily function, and changes in infarct volume on brain imaging.

The central hypothesis was ambitious: the peptide combination would produce 20% greater improvement in disability at six months than standard care.

It did not.

In the intention-to-treat analysis, which preserves the original randomization and is the most important test of efficacy, there was no significant difference in modified Rankin scores, Barthel Index scores, or survival. That is the headline result. Any honest reading of the paper has to start there.

The severe-stroke subgroup changed the conversation

The interesting result appeared among 27 patients whose baseline NIHSS score was at least 15, indicating a more severe stroke. At six months, patients in this subgroup who received EGF plus GHRP-6 had an average modified Rankin score of 2.6, compared with 4.7 in the control group. Lower is better. A score near 2 generally describes slight disability; a score near 5 describes severe dependence requiring constant care.

The difference reached statistical significance at p=0.03. Mortality risk was also lower in the treated subgroup, with a hazard ratio of 0.18 (95% confidence interval 0.03 to 0.96; p=0.045). Among patients with strokes in the middle cerebral artery territory, treated patients also showed greater infarct-volume reduction at 30 days (p=0.041).

Those numbers are striking. They are also fragile.

The authors themselves were careful in the abstract: "The Courage-2 study missed the primary endpoint but suggested potential benefit in moderate-to-severe stroke." That is a reasonable interpretation, provided the word "suggested" does the work.

The subgroup contained only 27 people. The mortality confidence interval was extremely wide, stretching from a very large benefit to a much smaller one. Several outcomes and thresholds were examined, which raises the chance that at least one positive result will appear by chance. The trial was open-label, so patients and treating clinicians knew which treatment was given, although the infarct-volume analysis was blinded.

The authors ran a sensitivity analysis using an NIHSS threshold of 12 and reported a similar pattern. That makes the signal more coherent, but it does not convert a negative phase 3 trial into a positive one. It identifies the population for the next trial.

Why combine EGF with GHRP-6?

A stroke does not injure the brain through one pathway. Loss of blood flow cuts off oxygen and glucose. Energy failure follows. Excitotoxic signaling, oxidative stress, inflammation, mitochondrial dysfunction, and programmed cell death then expand the damage around the infarct core. Reopening an artery with thrombolysis or thrombectomy can save tissue, but reperfusion can also add oxidative and inflammatory stress.

The EGF and GHRP-6 combination was developed as a multi-pathway neuroprotective strategy. EGF is a growth factor involved in cell survival and repair signaling. GHRP-6 is a synthetic hexapeptide best known as a ghrelin-receptor agonist and growth hormone secretagogue, but its experimental effects extend beyond growth hormone release.

A 2026 proteomic study examined the combination in a rat model of middle cerebral artery occlusion. Researchers found changes in 40 proteins at three hours and 223 proteins at 24 hours. The affected networks included neurotransmitter transport, reactive-oxygen-species detoxification, heat-shock responses, mitochondrial function, hypoxia signaling, and apoptosis. This was animal work, not proof of a human benefit, but it helps explain why the combination might work better in strokes severe enough to generate a large salvageable penumbra.

Earlier animal studies reported smaller infarcts and better neurologic outcomes after combined treatment. A small phase 1/2 trial then randomized 36 patients to one of two dose groups or standard care. That study was designed mainly around safety. It found two treatment-attributed serious events in one patient in the lower-dose group and reported encouraging functional trends, but it was far too small to establish efficacy.

COURAGE-2 was the necessary reality check. The biological story remained plausible. The average patient did not benefit.

Safety deserves a closer look

Serious adverse events occurred in 48 of the 188 participants. None was judged treatment-related by the study investigators. However, 30 of 95 treated patients experienced a serious event, compared with 18 of 93 controls. The reported odds ratio was 1.92, with a 95% confidence interval of 0.981 to 3.767.

Because the confidence interval narrowly crossed 1.0, the difference was not conventionally statistically significant. That does not make it meaningless. The numerical imbalance should be examined carefully in a follow-up study, especially because acute stroke patients are medically unstable and because EGF activates growth and repair pathways with effects that can vary by tissue and clinical context.

There is another practical distinction worth making. The COURAGE-2 regimen was an intravenous hospital treatment begun within 12 hours of stroke onset. It was not a wellness protocol, a recovery stack, or the subcutaneous GHRP-6 use discussed in bodybuilding communities. The formulation, route, dose, timing, and companion drug all differ. Nothing in this trial supports self-administering GHRP-6 after a stroke or adding it to a home peptide regimen.

We searched Reddit for relevant firsthand reports, but automated access was blocked and no verifiable testimonials about this hospital combination were available. More importantly, anecdotes about appetite, recovery, or gym use would not answer the clinical question here. Acute stroke treatment is one setting where trial outcomes should outrank community testimony completely.

What the result means for patients

For now, standard emergency stroke care does not change. Anyone with sudden facial droop, arm weakness, speech difficulty, vision loss, severe imbalance, or an unexplained severe headache needs emergency evaluation immediately. Time still determines eligibility for thrombolysis and mechanical thrombectomy. An experimental peptide combination is not a substitute for either.

The result matters because neuroprotection has been one of stroke medicine's hardest problems. Many treatments that protected neurons in animals failed in people. COURAGE-2 suggests that broad enrollment may have diluted a treatment effect concentrated in patients with more severe injury. That is possible. It is not proven.

A credible next study would enroll patients prospectively according to stroke severity rather than discovering the responsive group after the fact. It should blind outcome assessment, pre-register a single primary severity threshold, stratify for reperfusion treatment, and recruit enough patients to estimate mortality without an enormous confidence interval. It should also investigate the serious-adverse-event imbalance rather than dismissing it because the p value missed 0.05.

If that trial reproduces the severe-stroke effect, EGF plus GHRP-6 could become a candidate adjunct to reperfusion and standard supportive care. If it does not, COURAGE-2 will have been another subgroup mirage. Both outcomes are scientifically useful.

The Oria take

This is not a peptide breakthrough, at least not yet. It is a negative phase 3 trial with a specific and biologically credible subgroup signal.

That distinction matters. Peptide coverage often swings between two bad habits: calling every positive p value a breakthrough, or treating a missed primary endpoint as proof that the entire idea is dead. COURAGE-2 deserves neither reaction.

The full trial did not show better disability, daily function, or survival. The severe-stroke subgroup showed an effect large enough to justify another trial, but small enough to demand skepticism. The safety data also need a harder look. That is where the evidence sits today.

Evidence grade: C. Human randomized phase 3 data are available, but the primary analysis was negative. The positive findings came from a small severity subgroup and require prospective replication before they can support clinical use.

Sources

1. Garcia-del-Barco D, et al. “Phase III Open-Label, Randomized Clinical Trial of Epidermal Growth Factor and Growth Hormone Releasing Hexapeptide in Acute Ischemic Stroke.” Journal of Clinical Neuroscience. Published online July 16, 2026. PMID: 42462342. DOI: 10.1016/j.jocn.2026.112195.
2. “A discovery-based proteomic approach of epidermal growth factor and growth hormone-releasing peptide-6 in a model of acute ischemic stroke.” 2026. PMID: 42258095.
3. “Combination therapy of Epidermal Growth Factor and Growth Hormone-Releasing Hexapeptide in acute ischemic stroke: a phase I/II non-blinded, randomized clinical trial.” 2024. PMID: 38638315.
4. “Neuroprotective effect of epidermal growth factor plus growth hormone-releasing peptide-6 resembles hypothermia in experimental stroke.” 2016. PMID: 27665924.
5. “Assessment of dose-effect and therapeutic time window in preclinical studies of rhEGF and GHRP-6 coadministration for stroke therapy.” 2015. PMID: 26311576.

Medical disclaimer: This article is for education only and is not medical advice. EGF plus GHRP-6 is experimental for acute ischemic stroke and is not approved for self-treatment. Stroke is a medical emergency. Call emergency services immediately if symptoms appear. Oria exists to help readers understand emerging evidence, not to replace diagnosis, emergency care, or guidance from a licensed clinician.